Angiotensin-converting enzyme inhibition and food restriction in diabetic mice do not correct the increased sensitivity for ischemia-reperfusion injury

Cardiovascular Diabetology

Volumn 11, Issue , 2012, Pages

  Van der Mieren, Gerry ^a   Nevelsteen, Ines ^a   Vanderper, Annelies ^a   Oosterlinck, Wouter ^a   Flameng, Willem ^a   Herijgers, Paul ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Diabetes mellitus; In vivo contractility; Infarct size; Ischemia reperfusion; Metabolic syndrome

Indexed keywords

CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; LOW DENSITY LIPOPROTEIN RECEPTOR;

ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C57BL 6 MOUSE; CONTROLLED STUDY; DIET RESTRICTION; DISEASE ASSOCIATION; DISEASE MODEL; ENZYME INHIBITION; FISHER EXACT TEST; HEART INFARCTION SIZE; HEART LEFT VENTRICLE CONTRACTILITY; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; KNOCKOUT MOUSE; LEPTIN DEFICIENCY; METABOLIC SYNDROME X; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; POST HOC ANALYSIS; REPERFUSION INJURY; STATISTICAL SIGNIFICANCE; STUDENT T TEST; WEIGHT REDUCTION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BIOLOGICAL MARKERS; CALORIC RESTRICTION; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; LEPTIN; METABOLIC SYNDROME X; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, OBESE; MYOCARDIAL CONTRACTION; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; RECEPTORS, LDL; TIME FACTORS; VENTRICULAR FUNCTION, LEFT; VENTRICULAR PRESSURE;

EID: 84864406503     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-11-89     Document Type: Article

References (43)

1. Kereiakes DJ, Willerson JT. Metabolic syndrome epidemic. Circulation 2003, 108:1552-1553. 10.1161/01.CIR.0000093203.00632.2B, 14517151.
2. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27:1047-1053. 10.2337/diacare.27.5.1047, 15111519.
3. Dohi T, Miyauchi K, Kasai T, Kajimoto K, Kubota N, Tamura H, Yokoyama T, Kojima T, Yokoyama K, Kurata T, Daida H. Impact of metabolic syndrome on 10-year clinical outcomes among patients with acute coronary syndrome. Circ J 2009, 73:1454-1458. 10.1253/circj.CJ-08-1122, 19531901.
4. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998, 339:229-234. 10.1056/NEJM199807233390404, 9673301.
5. Marfella R, Di Filippo C, Esposito K, Nappo F, Piegari E, Cuzzocrea S, Berrino L, Rossi F, Giugliano D, D'Amico M. Absence of inducible nitric oxide synthase reduces myocardial damage during ischemia reperfusion in streptozotocin-induced hyperglycemic mice. Diabetes 2004, 53:454-462. 10.2337/diabetes.53.2.454, 14747298.
6. Aasum E, Hafstad AD, Severson DL, Larsen TS. Age-dependent changes in metabolism, contractile function and ischemic sensitivity in hearts from db/db mice. Diabetes 2003, 52:434-441.
7. Bouhidel O, Pons S, Souktani R, Zini R, Berdeaux A, Ghaleh B. Myocardial ischemic postconditioning against ischemia-reperfusion is impaired in ob/ob mice. Am J Physiol Heart Circ Physiol 2008, 295:H1580-H1586. 10.1152/ajpheart.00379.2008, 2759460, 18689499.
8. Van den Bergh A, Vanderper A, Vangheluwe P, Desjardins F, Nevelsteen I, Verreth W, Wuytack F, Holvoet P, Flameng W, Balligand JL, Herijgers P. Dyslipidemia in type II diabetic mice does not aggravate contractile impairment but increases ventricular stiffness. Cardiovasc Res 2008, 77:371-379.
9. Van den Bergh A, Flameng W, Herijgers P. Type II diabetic mice exhibit contractile dysfunction but maintain cardiac output by favourable loading conditions. Eur J Heart Fail 2006, 8:777-783. 10.1016/j.ejheart.2006.03.001, 16716661.
10. Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, Fonseca V, Gerstein HC, Grundy S, Nesto RW, Pignone MP, Plutzky J, Porte D, Redberg R, Stitzel KF, Stone NJ, , . American Heart Association American Diabetes Association, American Heart Association American Diabetes Association Primary prevention of cardiovascular disease in people with diabetes mellitus. A Scientific statement from the American Heart Association and the American Diabetes Association. Circulation 2007, 115:114-126. American Heart Association American Diabetes Association, American Heart Association American Diabetes Association.
11. Verreth W, De Keyzer D, Pelat M, Verhamme P, Ganame J, Bielicki JK, Mertens A, Quarck R, Benhabiles N, Marguerie G, Mackness B, Mackness M, Ninio E, Herregods MC, Balligand JL, Holvoet P. Weight-loss-associated induction of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma correlate with reduced atherosclerosis and improved cardiovascular function in obese insulin-resistant mice. Circulation 2004, 110:3259-3269. 10.1161/01.CIR.0000147614.85888.7A, 15533870.
12. Crandall DL, Goldstein BM, Gabel RA, Cervoni P. Hemodynamic effects of weight reduction in the obese rat. Am J Physiol 1984, 247:R266-R271.
13. Broderick TL, Belke T, Driedzic WR. Effects of chronic caloric restriction on mitochondrial respiration in the ischemic reperfused rat heart. Mol Cell Biochem 2002, 233:119-125. 10.1023/A:1015506327849, 12083365.
14. Velasquez MT, Bhathena SJ, Striffler JS, Thibault N, Scalbert E. Role of angiotensin-converting enzyme inhibition in glucose metabolism and renal injury in diabetes. Metabolism 1998, 47:7-11.
15. ACE Inhibitor Myocardial Infarction Collaborative Group Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. Circulation 1998, 97:2202-2212. ACE Inhibitor Myocardial Infarction Collaborative Group.
16. Mehta PM, Przyklenk K, Kloner RA. Cardioprotective effects of captopril in myocardial ischemia, ischemia/reperfusion and infarction. Eur Heart J 1990, 11:94-99.
17. Parlakpinar H, Ozer MK, Acet A. Effects of captopril and angiotensin II receptor blockers (AT1, AT2) on myocardial ischemia-reperfusion induced infarct size. Cytokine 2011, 56:688-694. 10.1016/j.cyto.2011.09.002, 21975128.
18. Yang X-P, Liu Y-H, Shesely EG, Bulagannawar M, Liu F, Carretero OA. Endothelial nitric oxide gene knock-out mice: cardiac phenotypes and the effect of angiotensin-converting enzyme inhibitor on myocardial ischemia/reperfusion injury. Hypertension 1999, 34:24-30. 10.1161/01.HYP.34.1.24, 10406819.
19. Liu YH, Yang XP, Sharov VG, Sigmon DH, Sabbath HN, Carretero OA. Paracrine systems in the cardioprotective effect of angiotensin-converting enzyme inhibitors on myocardial ischemia/reperfusion injury in rats. Hypertension 1996, 27:7-13. 10.1161/01.HYP.27.1.7, 8591891.
20. Nozawa Y, Miura T, Tsuchida A, Kita H, Fukuma T, Shimamoto K. Chronic treatment with an ACE inhibitor, temocapril, lowers the threshold for the infarct size-limiting effect of ischemic preconditioning. Cardiovac Drugs Ther 1999, 13:151-157.
21. Itoh S, Ding B, Shishido T, Lerner-Marmarosh N, Wang N, Maekawa N, Berk BC, Takeishi Y, Yan C, Blaxall BC, Abe J. Role of p90 ribosomal S6 kinase-mediated prorenin-converting enzyme in ischemic and diabetic myocardium. Circulation 2006, 113:1787-1798. 10.1161/CIRCULATIONAHA.105.578278, 16585392.
22. Wichi R, Farah V, Chen Y, Irigoyen MC, Morris M. Deficiency in angiotensin AT1a receptors prevents diabetes-induced hypertension. Am J Physiol Regul Integr Comp Physiol 2007, 292:R1184-R1189.
23. Van der Mieren G, Van den Bergh A, Nevelsteen I, Vanderper A, Flameng W, Herijgers P. Hypoxic preconditioning preserves cardiac contractility and reduces infarct size in vivo. The Open Surgery Journal 2008, 2:24-29.
24. Van den Bergh A, Flameng W, Herijgers P. Parameters of ventricular contractility in mice: influence of load and sensitivity to changes in inotropic state. Pflugers Arch 2008, 455:987-994. 10.1007/s00424-007-0362-8, 17932685.
25. Rodrigues B, Rosa KT, Medeiros A, Schaan BD, Brum PC, De Angelis K, Irigoyen MC. Hyperglycemia can delay left ventricular dysfunction but not autonomic damage after myocardial infarction in rodents. Cardiovasc Diabetol 2011, 10:26. 10.1186/1475-2840-10-26, 3084163, 21470409.
26. Miki T, Itoh T, Sunaga D, Miura T. Effects of diabetes on myocardial infarct size and cardioprotection by preconditioning and postconditioning. Cardiovasc Diabetol 2012, 11:67. 10.1186/1475-2840-11-67, 22694800.
27. Wölkart G, Pang X, Stessel H, Kirchengast M, Brunner F. Chronic endothelin-A receptor antagonism is as protective as angiotensin converting enzyme inhibition against cardiac dysfunction in diabetic rats. Br J Pharmacol 2007, 151:1187-1197. 2189828, 17572700.
28. Rui T, Zhang J, Xu X, Yao Y, Kao R, Martin M. Reduction of IL-33 expression exaggerates ischemia/reperfusion-induced myocardial injury in mice with diabetes mellitus. Cardiovasc Res 2012, 94:370-378. 10.1093/cvr/cvs015, 22258632.
29. Abozguia K, Clarke K, Lee L, Frenneaux M. Modification of myocardial substrate use as a therapy for heart failure. Nat Clin Pract Cardiovasc Med 2006, 3:490-498. 10.1038/ncpcardio0583, 16932766.
30. Marfella R, Esposito K, Nappo F, Siniscalchi M, Sasso FC, Portoghese M, Di Marino MP, Baldi A, Cuzzocrea S, Di Filippo C, Barboso G, Baldi F, Rossi F, D'Amico M, Giugliano D. Expression of angiogenic factors during acute coronary syndromes in human type 2 diabetes. Diabetes 2004, 53:2383-2391. 10.2337/diabetes.53.9.2383, 15331549.
31. Talukder MA, Kalyanasundaram A, Zuo L, Velayutham M, Nishijima Y, Periasamy M, Zweier JL. Is reduced SERCA2a expression detrimental or beneficial to postischemic cardiac function and injury? Evidence from heterozygous SERCA2a knockout mice. Am J Physiol Heart Circ Physiol 2008, 294:H1426-H1434.
32. Bugger H, Abel ED. Molecular mechanisms for myocardial mitochondrial dysfunction in the metabolic syndrome. Clin Sci 2008, 114:195-210. 10.1042/CS20070166, 18184113.
33. Hwang YC, Sato S, Tsai JY, Yan S, Bakr S, Zhang H, Oates PJ, Ramasamy R. Aldosereductase activation is a key component of myocardial response to ischemia. FASEB J 2002, 16:243-245.
34. Kaneko M, Bucciarelli L, Hwang YC, Lee L, Yan SF, Schmidt AM, Ramasamy R. Aldosereductase and AGE-RAGE pathways: key players in myocardial ischemic injury. Ann N Y Acad Sci 2005, 1043:702-709. 10.1196/annals.1333.081, 16037296.
35. McGaffin KR, Sun CK, Rager JJ, Romano LC, Zou B, Mathier MA, O'Doherty RM, McTiernan CF, O'Donnell CP. Leptin signalling reduces the severity of cardiac dysfunction and remodelling after chronic ischaemic injury. Cardiovasc Res 2008, 77:54-63.
36. McGaffin KR, Zou B, McTiernan CF, O'Donnell CP. Leptin attenuates cardiac apoptosis after chronic ischaemic injury. Cardiovasc Res 2009, 83:313-324. 10.1093/cvr/cvp071, 2701718, 19233863.
37. Van den Bergh A, Vangheluwe P, Vanderper A, Carmeliet P, Wuytack F, Janssens S, Flameng W, Holvoet P, Herijgers P. Food-restriction in obese dyslipidaemic diabetic mice partially restores basal contractility but not contractile reserve. Eur J Heart Fail 2009, 11:1118-1125. 10.1093/eurjhf/hfp156, 19926597.
38. Mitchell JR, Verweij M, Brand K, van de Ven M, Goemaere N, van den Engel S, Chu T, Forrer F, Müller C, de Jong M, van IJcken W, IJzermans JN, Hoeijmakers JH, de Bruin RW. Short-term dietaryrestriction and fasting precondition against ischemia reperfusion injury in mice. Aging Cell 2010, 9:40-53. 10.1111/j.1474-9726.2009.00532.x, 3412229, 19878145.
39. Yamagishi T, Bessho M, Yanagida S, Nishizawa K, Kusuhara M, Ohsuzu F, Tamai S. Severe, short-term food restriction improves cardiac function following ischemia/reperfusion in perfused rat hearts. Heart Vessels 2010, 25:417-425. 10.1007/s00380-009-1222-6, 20676965.
40. Takeishi Y, Bhagwat A, Ball NA, Kirkpatrick DL, Periasamy M, Walsh RA. Effect of angiotensin-converting enzyme inhibition on protein kinase C and SR proteins in heart failure. Am J Physiol Heart Circ Physiol 1999, 276:H53-H62.
41. Gross ML, Heiss N, Weckbach M, Hansen A, El-Shakmak A, Szabo A, Münter K, Ritz E, Amann K. ACE-inhibition is superior to endothelin A receptor blockade in preventing abnormal capillary supply and fibrosis of the heart in experimental diabetes. Diabetologia 2004, 47:316-324. 10.1007/s00125-003-1309-z, 14727024.
42. Ren L, Liu N, Zhi H, Li Y, Li Y, Tang R, Sheng Z. Vasculoprotective effects of rosiglitazone through modulating renin-angiotensin system in vivo and vitro. Cardiovasc Diabetol 2011, 10:10. 10.1186/1475-2840-10-10, 3039565, 21269478.
43. Ichinomiya T, Cho S, Higashijima U, Matsumoto S, Maekawa T, Sumikawa K. High-dose fasudil preserves postconditioning against myocardial infarction under hyperglycemia in rats: role of mitochondrial KATP channels. Cardiovasc Diabetol 2012, 11:28. 10.1186/1475-2840-11-28, 3350454, 22436066.